Future market for drug development is not intended to be high end throughput. Dedicated medicines are in the core business of new players and start-ups devoted to the cure of orphan diseases.

V-Nano intends to provide its partners with a new medical model, as future drugs are not and will not be supported by large expensive laboratories and filling lines.

If you want to be efficient, you need to be small.

“Start-ups need flexibility and high-quality supply to serve global markets.”

V-Nano built its team to support this vision: highly skilled staff in sterile manufacturing is one of its pillars, the other is the equipment. Isolator is our sterile manufacturing standard: the future of sterile manufacturing will be human-intervention free, bringing sterile levels to the highest standards.

Our aim is to support the broadest range of new molecules, from placebo to more complex molecules such as antibody drug conjugate (ADC) using pyrrolobenzodiazepine (PBD) payloads. Future nanotechnology-enabled products will use cytotoxic or high potency active pharmaceutical ingredient (API) and will be prepared in safe and sterile environment: V-Nano brings this feature to market both at clinical and at commercial scale.


This is V-Nano’s vision for the future